Asset Details
Do you wish to reserve the book?
Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
Do you wish to request the book?
Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
2025
Overview
In recent years there has been a growing interest in metastasis directed radiotherapy (MDRT) in hormone-sensitive oligometastatic prostate cancer. The role of MDRT in castration resistant prostate cancer (CRPC) patients remains controversial. Our study retrospectively compared MDRT to standard of care (SOC) in oligometastatic/oligoprogressive CRPC patients staged by PSMA PET CT. Patients either received SOC or MDRT with continuation of androgen deprivation therapy (ADT). Investigated endpoints contained biochemical progression-free survival (bPFS), overall survival (OS) and freedom from second line therapy (FFSLT). In this retrospective monocenter study, all patients with PSMA PET between January 2014 and July 2018 were screened. 55 oligometastatic/oligoprogressive CRPC patients were identified and further analysed, 34 received MDRT and 21 SOC. Baseline characteristics were similarly distributed between groups. Kaplan–Meier estimates suggested a trend for improved bPFS (
p
= 0.10) and improved OS (
p
= 0.01) by MDRT. Additionally, FFSLT was significantly prolonged in MDRT patients (
p
= 0.006). Multivariate cox regression analyses revealed MDRT as the only parameter that was significantly associated with bPFS (hazard ratio 0.36,
p
= 0.048) and OS (hazard ratio 0.14,
p
= 0.006). No high-grade radiation induced toxicities were observed. In our study MDRT was a well-tolerated treatment option with low toxicity in oligometastatic/oligoprogressive CRPC patients, resulting in improved OS and freedom from second-line therapy and a potential improvement of bPFS compared to SOC.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Aged
/ Androgen Antagonists - therapeutic use
/ Antigens
/ Antigens, Surface - metabolism
/ Castration resistant prostate cancer
/ Glutamate Carboxypeptidase II - metabolism
/ Humanities and Social Sciences
/ Humans
/ Male
/ Neoplasm Metastasis - radiotherapy
/ Oligometastatic prostate cancer
/ Oligoprogressive prostate cancer
/ Patients
/ Positron emission tomography
/ Positron Emission Tomography Computed Tomography
/ Prostatic Neoplasms, Castration-Resistant - diagnostic imaging
/ Prostatic Neoplasms, Castration-Resistant - mortality
/ Prostatic Neoplasms, Castration-Resistant - pathology
/ Prostatic Neoplasms, Castration-Resistant - radiotherapy
/ PSMA PET
/ Science
/ Survival
/ Toxicity
